1345614-59-6
基本信息
AM095 sodium
AM095 >=98% (HPLC)
AM-095
AM095
AM 095
AM095 hydrochloride
AM095 (Sodium Salt)
sodium,2-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]acetate
(2-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]acetic acid) sodium salt
4'-[3-Methyl-4-[[[(1R)-1-phenylethoxy]carbonyl]amino]-5-isoxazolyl]-[1,1'-biphenyl]-4-acetic acid sodium salt (1:1)
物理化学性质
| 储存条件 | room temp |
| 溶解度 | ≥23.9 mg/mL in DMSO; insoluble in H2O; ≥16.77 mg/mL in EtOH with ultrasonic |
| 形态 | 粉末 |
| 颜色 | 白色至米色 |
图谱信息
4'-[3-甲基-4-[[[(1R)-1-苯基乙氧基]羰基]氨基]-5-异恶唑基]联苯-4-乙酸钠盐(1345614-59-6)质谱(MS)4'-[3-甲基-4-[[[(1R)-1-苯基乙氧基]羰基]氨基]-5-异恶唑基]联苯-4-乙酸钠盐(1345614-59-6)核磁图(1HNMR)4'-[3-甲基-4-[[[(1R)-1-苯基乙氧基]羰基]氨基]-5-异恶唑基]联苯-4-乙酸钠盐价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/02/08 | HY-16039 | 4'-[3-甲基-4-[[[(1R)-1-苯基乙氧基]羰基]氨基]-5-异恶唑基]联苯-4-乙酸钠盐 AM095 | 1345614-59-6 | 1 mg | 659元 |
| 2025/02/08 | HY-16039 | 4'-[3-甲基-4-[[[(1R)-1-苯基乙氧基]羰基]氨基]-5-异恶唑基]联苯-4-乙酸钠盐 AM095 | 1345614-59-6 | 5mg | 1450元 |
| 2025/02/08 | HY-16039 | 4'-[3-甲基-4-[[[(1R)-1-苯基乙氧基]羰基]氨基]-5-异恶唑基]联苯-4-乙酸钠盐 AM095 | 1345614-59-6 | 10mM * 1mLin DMSO | 1526元 |
常见问题列表
LPA 1 receptor
AM095 is a potent LPA 1 receptor antagonist because it inhibits GTPγS binding to Chinese hamster ovary (CHO) cell membranes overexpressing recombinant human or mouse LPA 1 with IC 50 values of 0.98 and 0.73 μM, respectively. AM095 inhibits LPA-driven chemotaxis of CHO cells overexpressing mouse LPA 1 (IC 50 =778 nM) and human A2058 melanoma cells (IC 50 =233 nM). The IC 50 of AM095 in the human LPA 1 GTPγS binding assay is comparable with that of our previously published compound AM966 (IC 50 =0.98±0.17 μM) and the Debio-0719 compound (IC 50 =0.60±0.04 μM). AM095 inhibits the LPA-induced calcium flux of CHO cells stably transfected with human or mouse LPA 1 . The IC 50 for AM095 antagonism of LPA-induced calcium flux of human or mouse LPA 1 -transfected CHO cells is 0.025 and 0.023 μM, respectively.
AM095 has high oral bioavailability and a moderate half-life and is well tolerated at the doses tested in rats and dogs after oral and intravenous dosing. After oral (10 mg/kg) dosing in rats, AM095 plasma concentrations peaked at 2 h with a C max of 41 μM, thereafter decreasing to 10 nM by 24 h. After intravenous (2 mg/kg) dosing, a C max of 12 μM is observed within 15 min, which also decreased to approximately 10 nM by 24 h, yielding a t 1/2 of 1.79 h. In dogs, a single oral dose of 5 mg/kg yielded a peak plasma concentration of 21 μM within 15 min of dosing, which then decreased to 10 nM by 24 h. In contrast, an intravenous dose of 2 mg/kg resulted in a C max of 11 μM within 15 min and decreased to 15 nM by 8 h, yielding a t 1/2 of 1.5 h.